Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.
The main purpose of this study is to investigate the safety and efficacy of an investigational treatment for head lice infestation against a placebo.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Active Comparator | Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
|
| 2 | Active Comparator | Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
|
| 3 | Active Comparator | Subjects are treated either once (day1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
|
| 4 | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo | Drug | Vehicle Only |
| |
| BGC20-0582 |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Cure | Count of participants with No live lice | Day 15 or 22 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Global Health Associates of Miami Inc | Florida City | Florida | 33034 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | 2.5% BGC20-0582 | Active Comparator: 1 Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or 2.5% BGC20-0582 topically. Following application of the BG20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
| FG001 | 10% BGC20-0582 | Active Comparator: 2 Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or 10% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
| FG002 | 12.5% BGC20-0582 | Active Comparator: 3 Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or 12.5% BGC20-0582 topically. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
| FG003 | Vehicle | Placebo Comparator: 4 |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | 2.5% BGC20-0582 | |
| BG001 | 10% BGC20-0582 | |
| BG002 | 12.5% BGC20-0582 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Clinical Cure | Count of participants with No live lice | Posted | Count of Participants | Participants | Day 15 or 22 |
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | 2.5% BGC20-0582 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Application site irritation | General disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jessie Stockwell | Boston Scientific Corporation | 612-618-1136 | jessie.stockwell@bsci.com |
Not provided
| ID | Term |
|---|---|
| D010373 | Lice Infestations |
| ID | Term |
|---|---|
| D004478 | Ectoparasitic Infestations |
| D012876 | Skin Diseases, Parasitic |
| D010272 | Parasitic Diseases |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair. |
|
| BG003 | Vehicle |
| BG004 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | 12.5% BGC20-0582 | Active Comparator: 3 Subject's are treated either once (day 1) or twice (day 1 and 7) with either placebo or 12.5% BG20-0582 TOPICALLY. Following application of the BGC20-0582 lice treatment gel or placebo, the product is rinsed from the subject's hair. |
| OG003 | Vehicle | Placebo Comparator: 4 |
|
|
| 0 |
| 59 |
| 13 |
| 59 |
| EG001 | 10% BGC20-0582 | 0 | 59 | 10 | 59 |
| EG002 | 12.5% BGC20-0582 | 0 | 56 | 16 | 56 |
| EG003 | Vehicle | 0 | 56 | 11 | 56 |
| Application site pruritis | General disorders | Systematic Assessment |
|
| Dandruff | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
| D012874 |
| Skin Diseases, Infectious |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |